Riskpilot← Back to searchSign inGet full accessCHANEXA MEDICO AB
ABActiveOrg 5569175192SollentunaPhysiotherapy activities · NACE 8695Est. 20131 employees
Revenue 2025
SEK 1,8M
+73% vs 2024
EBITDA margin
24.5%
+196% vs 2024
Equity ratio
52.6%
Financial strength
Net profit 2025
SEK 346K
-24% vs 2024
| Revenue | SEK 1,8M | +73% |
| EBITDA | SEK 450K | +196% |
| Net profit | SEK 346K | -24% |
| Total assets | SEK 2,8M | +5% |
| Equity | SEK 1,4M | -5% |
| Employees | 1 | — |
Legal name
CHANEXA MEDICO AB
Org number
5569175192
Legal form
Aktiebolag
NACE code
8695 · Physiotherapy activities
Founded
2 januari 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva hälso- och sjukvård, utbildning inom densamma, äga och förvalta fast och lös egendom och värdepapper samt idka därmed förenlig verksamhet.
Address
Sollentuna
Email
dr_zhaeentan_f@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 166 | 1 078 | 714 | 1 062 | 1 835 |
| Staff expenses | — | −1 679 | −1 330 | −1 363 | −1 218 |
| EBITDA | −393 | −840 | −737 | −470 | 450 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −393 | −840 | −737 | −470 | 450 |
| Net financials | 19 | 808 | 1 710 | 1 030 | 3 |
| Profit before tax | 109 | 17 | 718 | 593 | 450 |
| Tax | −39 | −13 | −161 | −139 | −104 |
| Net profit | 70 | 4 | 557 | 454 | 346 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 244 | 2 377 | 2 896 | 2 619 | 2 753 |
| Equity | 1 565 | 1 382 | 1 449 | 1 528 | 1 448 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 26 | 392 | 589 | 266 | 478 |
| Total debt | 26 | 392 | 589 | 266 | 478 |
EBITDA margin
24.5%
This company
15.8%
Market median
+55% vs market
20212025
Equity ratio
52.6%
This company
38.2%
Market median
+38% vs market
20212025
Return on equity
23.9%
This company
18.4%
Market median
+30% vs market
20212025
Net profit margin
18.9%
This company
8.1%
Market median
+133% vs market
20212025
Asset turnover
0.67×
This company
1.12×
Market median
-40% vs market
20212025
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FZ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CHANEXA MEDICO AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fariba Zhaeentan | Chief Executive Officer | 0 companies |
| Chanelle Victoria A Scheffer | Deputy Board Member | 0 companies |